

Saviana Gandolfo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2110533/publications.pdf>

Version: 2024-02-01

27
papers

512
citations

933264

10
h-index

677027

22
g-index

28
all docs

28
docs citations

28
times ranked

696
citing authors

#	ARTICLE	IF	CITATIONS
1	Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts. Computational and Structural Biotechnology Journal, 2022, 20, 471-484.	1.9	7
2	Peripheral Nervous System Involvement in Sjögren's Syndrome: Analysis of a Cohort From the Italian Research Group on Sjögren's Syndrome. Frontiers in Immunology, 2021, 12, 615656.	2.2	12
3	Ultrasound and Bioptic Investigation of Patients with Primary Sjögren's Syndrome. Journal of Clinical Medicine, 2021, 10, 1171.	1.0	10
4	A biomarker for lymphoma development in Sjogren's syndrome: Salivary gland focus score. Journal of Autoimmunity, 2021, 121, 102648.	3.0	24
5	Shared Pathogenetic Features Between Common Variable Immunodeficiency and Sjögren's Syndrome: Clues for a Personalized Medicine. Frontiers in Immunology, 2021, 12, 703780.	2.2	3
6	A federated AI strategy for the classification of patients with Mucosa Associated Lymphoma Tissue (MALT) lymphoma across multiple harmonized cohorts. , 2021, 2021, 1666-1669.		0
7	TREX1 variants in Sjogren's syndrome related lymphomagenesis. Cytokine, 2020, 132, 154781.	1.4	18
8	Sjögren's Syndrome: The Clinical Spectrum of Male Patients. Journal of Clinical Medicine, 2020, 9, 2620.	1.0	26
9	Primary Sjögren's Syndrome of Early and Late Onset: Distinct Clinical Phenotypes and Lymphoma Development. Frontiers in Immunology, 2020, 11, 594096.	2.2	45
10	Overcoming the Barriers That Obscure the Interlinking and Analysis of Clinical Data Through Harmonization and Incremental Learning. IEEE Open Journal of Engineering in Medicine and Biology, 2020, 1, 83-90.	1.7	9
11	Validation of thymic stromal lymphopoietin as a biomarker of primary Sjögren's syndrome and related lymphoproliferation: results in independent cohorts. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 189-194.	0.4	0
12	Predicting lymphoma development in patients with Sjögren's syndrome. Expert Review of Clinical Immunology, 2019, 15, 929-938.	1.3	31
13	Emerging drugs for primary Sjögren's syndrome. Expert Opinion on Emerging Drugs, 2019, 24, 121-132.	1.0	10
14	Articular and Peripheral Nervous System Involvement Are Linked to the Long-Term Outcome in Primary Sjögren's Syndrome: The Relevance of Single Organ Manifestations Rather Than a Composite Score as Predictors. Frontiers in Immunology, 2019, 10, 1527.	2.2	5
15	Medical data quality assessment: On the development of an automated framework for medical data curation. Computers in Biology and Medicine, 2019, 107, 270-283.	3.9	67
16	AB0166â€¦ENHANCING THE QUALITY OF CLINICAL DATA THROUGH DATA CURATION IN PRIMARY SJÖGREN'S SYNDROME. , 2019, , .		0
17	SAT0190â€¦LYMPHOMA IN PRIMARY SJÖGREN'S SYNDROME: A RETROSPECTIVE CLINICAL STUDY WITH PATIENTS FROM THE UPA (UDINE, PISA, ATHENS) GROUP. , 2019, , .		0
18	Enhancing medical data quality through data curation: a case study in primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 90-96.	0.4	2

#	ARTICLE	IF	CITATIONS
19	Thymic stromal lymphopoietin expression from benign lymphoproliferation to malignant B-cell lymphoma in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 55-64.	0.4	2
20	Double anti-B cell and anti-BAFF targeting for the treatment of primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 199-208.	0.4	9
21	Sjögren's Syndrome. , 2018, , 323-335.		0
22	The evaluation of disease activity in Sjögren's syndrome based on the degree of MALT involvement: glandular swelling and cryoglobulinaemia compared to ESSDAI in a cohort study. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 150-156.	0.4	7
23	Cryoglobulinemia in Sjögren Syndrome: A Disease Subset that Links Higher Systemic Disease Activity, Autoimmunity, and Local B Cell Proliferation in Mucosa-associated Lymphoid Tissue. <i>Journal of Rheumatology</i> , 2017, 44, 1179-1183.	1.0	33
24	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides,)	2.5	107
25	Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 719-720.	0.4	3
26	Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren's syndrome: follow-up after the end of the phase II open-label BELISS study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 311-4.	0.4	15
27	Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study. <i>Rheumatology</i> , 2015, 54, kev257.	0.9	66